Rituxan

Oncology

Indications and Usage

Non–Hodgkin's Lymphoma (NHL)

RITUXAN is indicated for the treatment of adult patients with:

Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent.
Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

RITUXAN is indicated for the treatment of pediatric patients aged 6 months and older with:

Previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.

Chronic Lymphocytic Leukemia (CLL)

RITUXAN, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive CLL.

Rheumatoid Arthritis (RA)

RITUXAN, in combination with methotrexate, is indicated for the treatment of adult patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)

RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).

Pemphigus Vulgaris (PV)

RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.

More than 200,000 clinicians have integrated PrescriberPoint into their clinical workflows

HOW IT WORKS

The easy way to access samples

Create Free AccountRequest, track, and manage samples from multiple brands

Connect with a RepHave access to pharma representatives in one place to request your samples

Get your SampleManage your reps and samples in one place

WHO IS PRESCRIBERPOINT

Increasing patient access to medications they need

At PrescriberPoint, we're revolutionizing how healthcare providers get patients the medications they need. We craft solutions that help providers address the challenges in patient access and improve outcomes.

200K+Visitors Each Month

100K+Engagements Each Month

1M+Resources Viewed

WHAT HCPS ARE SAYING

This tool has transformed the way we order drug samples. Not having to interact with reps has saved us so much time and hassle. Plus, the ability to track orders in real-time is incredibly convenient. Our patients benefit greatly from the streamlined processCardiologistSan Francisco, CA

We can't imagine going back to the old way of ordering samples. The seamless integration with our existing systems and the timely scheduled deliveries have made our workflow so much more efficient. Our patients are receiving better care thanks to this tool.PediatricianChicago, IL

Ordering samples is now a breeze! The interface is user-friendly, and scheduling deliveries has never been easier. This tool has truly enhanced our patient care by ensuring they get the medications they need promptly.Family PhysicianAustin, TX

FAQs

All you need to know to order samples

Currently, PrescriberPoint is available only in the U.S, but we are excited to expand our reach in the future! Stay connected by following us or signing up for our newsletter to get the latest updates, including announcements about new market launches.

Other Oncology Samples

ImbruvicaPharmacyclics LLC

RituxanGenentech, Inc.

CalquenceAstraZeneca Pharmaceuticals LP

VenclextaAbbVie Inc.